Differential Regulation of Breast Cancer-Associated Genes by Progesterone Receptor Isoforms PRA and PRB in a New Bi-Inducible Breast Cancer Cell Line

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Khan, Junaid A ^a,b,d   Bellance, Catherine ^a,b   Guiochon Mantel, Anne ^a,b,c   Lombès, Marc ^a,b,c   Loosfelt, Hugues ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITY OF AGRICULTURE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; MESSENGER RNA; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

AMPHIREGULIN GENE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER ASSOCIATED GENE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HEPARIN BINDING GROWTH FACTOR GENE; HUMAN; HUMAN CELL; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HORMONE ANTAGONISTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIFEPRISTONE; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; TRANSCRIPTIONAL ACTIVATION;

EID: 84866699934     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045993     Document Type: Article

References (82)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
2. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, et al. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J. 9: 1603-1614.
3. Giangrande PH, McDonnell DP (1999) The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54: 291-313; discussion 313-294.
4. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM, (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289: 1751-1754.
5. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM, (2003) Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A 100: 9744-9749.
6. Mani SK, Reyna AM, Chen JZ, Mulac-Jericevic B, Conneely OM, (2006) Differential response of progesterone receptor isoforms in hormone-dependent and-independent facilitation of female sexual receptivity. Mol Endocrinol 20: 1322-1332.
7. Bain DL, Franden MA, McManaman JL, Takimoto GS, Horwitz KB, (2001) The N-terminal region of human progesterone B-receptors: biophysical and biochemical comparison to A-receptors. J Biol Chem 276: 23825-23831.
8. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP, (1999) Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 13: 910-924.
9. Mote PA, Bartow S, Tran N, Clarke CL, (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72: 163-172.
10. Mote PA, Graham JD, Clarke CL (2007) Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Found Symp Proc: 77-107.
11. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, et al. (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55: 5063-5068.
12. McGowan EM, Saad S, Bendall LJ, Bradstock KF, Clarke CL, (2004) Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat 83: 211-220.
13. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R, (2004) Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131: 3469-3479.
14. Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, et al. (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer. 39: 236-248.
15. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, et al. (2006) Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467-1470.
16. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, et al. (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61: 4576-4582.
17. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E, (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A 95: 696-701.
18. Wargon V, Helguero LA, Bolado J, Rojas P, Novaro V, et al. (2009) Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat 116: 449-460.
19. Wargon V, Fernandez SV, Goin M, Giulianelli S, Russo J, et al. (2011) Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat 126: 319-332.
20. Faivre EJ, Daniel AR, Hillard CJ, Lange CA, (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22: 823-837.
21. Pierson-Mullany LK, Lange CA, (2004) Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 24: 10542-10557.
22. Mani SK, Allen JM, Lydon JP, Mulac-Jericevic B, Blaustein JD, et al. (1996) Dopamine requires the unoccupied progesterone receptor to induce sexual behavior in mice. Mol Endocrinol 10: 1728-1737.
23. Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombes M, et al. (2011) p38 and p42/44 MAPKs Differentially Regulate Progesterone Receptor A and B Isoform Stabilization. Mol Endocrinol 25: 394-408.
24. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, et al. (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277: 5209-5218.
25. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB, (2005) Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19: 574-587.
26. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, et al. (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19: 2713-2735.
27. Hovland AR, Powell RL, Takimoto GS, Tung L, Horwitz KB, (1998) An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J Biol Chem 273: 5455-5460.
28. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, et al. (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868-3877.
29. Lange CA, Shen T, Horwitz KB, (2000) Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A 97: 1032-1037.
30. Shen T, Horwitz KB, Lange CA, (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21: 6122-6131.
31. Chauchereau A, Loosfelt H, Milgrom E, (1991) Phosphorylation of transfected wild type and mutated progesterone receptors. J Biol Chem 266: 18280-18286.
32. Beck CA, Zhang Y, Weigel NL, Edwards DP, (1996) Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271: 1209-1217.
33. Leonhardt SA, Altmann M, Edwards DP, (1998) Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay. Mol Endocrinol 12: 1914-1930.
34. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, et al. (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7: 1244-1255.
35. Musgrove EA, Lee CS, Sutherland RL, (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: 5032-5043.
36. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, et al. (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11: 1593-1607.
37. Clarke CL, Sutherland RL, (1990) Progestin regulation of cellular proliferation. Endocr Rev 11: 266-301.
38. Horwitz KB, Sartorius CA, (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93: 3295-3298.
39. Horwitz KB, (1992) The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13: 146-163.
40. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, et al. (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 107: 2989-2994.
41. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, et al. (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109: 2742-2747.
42. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
43. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, et al. (2004) Clinical relevance of amphiregulin and VEGF in primary breast cancers. Int J Cancer 111: 733-740.
44. Smid-Koopman E, Kuhne LC, Hanekamp EE, Gielen SC, De Ruiter PE, et al. (2005) Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines. J Soc Gynecol Investig 12: 285-292.
45. Faivre EJ, Lange CA, (2007) Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 27: 466-480.
46. Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, et al. (2007) Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 72: 188-201.
47. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB, (2003) Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 8: 257-268.
48. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, et al. (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10: 2751-2760.
49. Leo JC, Wang SM, Guo CH, Aw SE, Zhao Y, et al. (2005) Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int J Cancer 117: 561-568.
50. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, et al. (2006) Progesterone receptors (PR)-B and-A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20: 2656-2670.
51. Afhuppe W, Sommer A, Muller J, Schwede W, Fuhrmann U, et al. (2009) Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J Steroid Biochem Mol Biol 113: 105-115.
52. McGowan EM, Clarke CL, (1999) Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13: 1657-1671.
53. Lessard J, Aicha SB, Fournier A, Calvo E, Lavergne E, et al. (2007) Characterization of the RSL1-dependent conditional expression system in LNCaP prostate cancer cells and development of a single vector format. Prostate 67: 808-819.
54. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB, (2002) New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 277: 27793-27800.
55. Peng J, Jordan VC, (2010) Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. Int J Oncol 36: 451-458.
56. Bake S, Ma L, Sohrabji F, (2008) Estrogen receptor-alpha overexpression suppresses 17beta-estradiol-mediated vascular endothelial growth factor expression and activation of survival kinases. Endocrinology 149: 3881-3889.
57. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ, (2006) The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 106: 2576-2582.
58. Clarke RB, Howell A, Potten CS, Anderson E, (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57: 4987-4991.
59. Russo J, Ao X, Grill C, Russo IH, (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53: 217-227.
60. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, et al. (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468: 103-107.
61. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, et al. (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102.
62. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, et al. (1999) Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 5: 395-403.
63. Bordoli MR, Stiehl DP, Borsig L, Kristiansen G, Hausladen S, et al. (2011) Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene 30: 548-560.
64. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A, (2011) The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 1816: 119-131.
65. Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, et al. (2011) Amphiregulin exosomes increase cancer cell invasion. Curr Biol 21: 779-786.
66. Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, et al. (2010) HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int J Cancer 127: 2707-2717.
67. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, et al. (2008) Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561.
68. Hagan CR, Regan TM, Dressing GE, Lange CA, (2011) ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol 31: 2439-2452.
69. Zhang Z, Funk C, Roy D, Glasser S, Mulholland J, (1994) Heparin-binding epidermal growth factor-like growth factor is differentially regulated by progesterone and estradiol in rat uterine epithelial and stromal cells. Endocrinology 134: 1089-1094.
70. Faivre E, Skildum A, Pierson-Mullany L, Lange CA, (2005) Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 70: 418-426.
71. Graham JD, Roman SD, McGowan E, Sutherland RL, Clarke CL, (1995) Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 270: 30693-30700.
72. Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, et al. (2010) Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem 285: 22059-22066.
73. Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, et al. (2010) The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol 24: 2126-2138.
74. Daniel AR, Faivre EJ, Lange CA, (2007) Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 21: 2890-2906.
75. Daniel AR, Lange CA, (2009) Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A 106: 14287-14292.
76. Moore NL, Narayanan R, Weigel NL, (2007) Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids 72: 202-209.
77. Narayanan R, Adigun AA, Edwards DP, Weigel NL, (2005) Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 25: 264-277.
78. Narayanan R, Edwards DP, Weigel NL, (2005) Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol 25: 2885-2898.
79. Abdel-Hafiz HA, Horwitz KB, (2012) Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol 13: 10.
80. Palli SR, Kapitskaya MZ, Kumar MB, Cress DE, (2003) Improved ecdysone receptor-based inducible gene regulation system. Eur J Biochem 270: 1308-1315.
81. Georgiakaki M, Chabbert-Buffet N, Dasen B, Meduri G, Wenk S, et al. (2006) Ligand-controlled Interaction of HBO1 with the N-terminal Transactivating Domain of Progesterone Receptor Induces SRC-1-dependent Co-activation of Transcription. Mol Endocrinol 20: 2122-2140.
82. Amazit L, Roseau A, Khan JA, Chauchereau A, Tyagi RK, et al. (2011) Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity. Mol Endocrinol 25: 394-408.